人可溶性血管内皮生长因子受体1抑制白血病细胞增殖的研究  

Inhibition of Leukemic Cell Proliferation by Human Soluble VEGF-R1

作　　者：朱晶[1] 宋艳秋[1] 李薇[1] 王冠军[1] 

机构地区：[1]吉林大学第一医院血液肿瘤科,长春130021

出　　处：《中国实验血液学杂志》2007年第1期168-174,共7页Journal of Experimental Hematology

摘　　要：本研究通过体外实验探讨人可溶性血管内皮生长因子受体1(sFLT-1)对白血病细胞增殖的抑制作用。用RT-PCR检测白血病细胞株K562、HL-60、U937和骨髓LTC-ICVEGFmRNA、VEGF-R1(FLT-1)mRNA的表达,用流式细胞术检测上述细胞VEGF和VEGF-R1(FLT-1)的表达,ELISA法检测细胞培养上清中VEGF的含量,将sFLT-1加入K562、HL-60白血病细胞株和骨髓LTC-IC培养体系中,应用MTT法计算细胞生长的抑制率。结果显示:白血病细胞株K562、HL-60、U937和骨髓LTC-IC均表达VEGF,以K562表达VEGF量最高。K562和HL-60细胞株还表达FLT-1,U937细胞和骨髓LTC-IC表达的FLT-1表达量很低。sFLT-1明显抑制白血病细胞株K562及HL-60的生长,并且随着sFLT-1浓度的增加,其抑制率增加,以用药后48小时抑制作用最明显。结论:sFLT-1能够抑制某些白血病细胞株的生长,其抑制效应随用药浓度的增加而增加,而sFLT-1对正常骨髓细胞增殖无影响。The current study was purposed to investigate the inhibitory effect of human soluble vascular endothelial growth factor-1 （ sFLT-1 ） on the proliferation of leukemic cells in vitro. Reverse transcription-polymerase chain reaction （RT-PCR） was used to detect the VEGF mRNA and VEGF-R1 （ FLT-1 ） mRNA in K562, HL60, U937 leukemic cell lines and bone marrow LTC-IC. Flow cytometry was used to detect the VEGF and VEGF-R1 （ FLT-1 ） in all above-mentioned cells. VEGF concentrations in the cell culture supernatants were determined by enzyme-linked immunosorbent assay （ELISA）. Cell proliferation was determined by MTT after adding sFLT-1 to K562, HL60 and LTC-IC culture system. The result showed that expression of VEGF could be detected in K562, HL60, U937 leukemic cell lines and LTC- IC, especially K562, K562 and HL60 cell lines also expressed FLT-1, but a little expression was found in U937 and LTC-IC. sFLT-1 could effectively inhibit the growth of K562 and HL60 cell lines in dose-dependent manner. The highest inhibition rate was found at 48 hours after adding sFLT-1. It is concluded that sFLT-1 can inhibit the growth of some leukemic cell lines, and the inhibition effect enhances as the concentration of the sFLT-1 increase, but sFLT -1 not influence the proliferation of normal marrow cells.

关 键 词：VEGF FLT-1 白血病细胞 

分 类 号：R733.7[医药卫生—肿瘤] R329.28[医药卫生—临床医学]